logo
  

ANI Pharma Q1 Profit Tops Estimates

ANI Pharmaceuticals, Inc. (ANIP) reported first quarter adjusted non-GAAP earnings per share of $1.04, flat with prior year. On average, three analysts polled by Thomson Reuters expected the company to report profit per share of $0.71, for the quarter. Analysts' estimates typically exclude special items. GAAP net income was $0.1 million, and GAAP earnings per share was $0.01, for the quarter.

First quarter net revenues were $54.5 million compared to $49.8 million, last year. Analysts expected revenue of $46.8 million, for the quarter.

Cash and cash equivalents were $25.1 million, net accounts receivable was $91.9 million, as of March 31, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
RELATED NEWS
Follow RTT